{"doi":"10.1111/ejh.14191","title":"Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet <scp>PCR</scp>","abstract":"<jats:title>Abstract</jats:title><jats:p>Although several promising approaches for the treatment of relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long‐term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously untreated DLBCL, but data on the repeated assessment of MRD in the dynamic course of rrDLBCL is limited. Here, we present an approach leveraging cost‐ and time‐sensitivity of digital droplet (dd)PCR to repeatedly assess MRD in rrDLBCL and present proof‐of‐principle for its ability to predict outcomes.</jats:p>","journal":"European Journal of Haematology","year":2024,"id":647611,"datarank":0.4105170264772885,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.08093333987685551,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.08093333987685551,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":8,"citers_with_citation_signal":6,"citers_with_endowment":6,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1687382,"name":"Yannick d'Hargues","orcid":null,"position":1,"is_corresponding":false},{"id":1687383,"name":"Fanni Kleinert","orcid":null,"position":2,"is_corresponding":false},{"id":1687384,"name":"Julia Mattlener","orcid":null,"position":3,"is_corresponding":false},{"id":84392,"name":"Jonathan Weiss","orcid":null,"position":4,"is_corresponding":false},{"id":1687385,"name":"Fabian Franzen","orcid":null,"position":5,"is_corresponding":false},{"id":1366353,"name":"Christian Becker","orcid":"0000-0002-1716-7208","position":6,"is_corresponding":false},{"id":1220845,"name":"Kerstin Becker","orcid":"0009-0009-7897-7181","position":7,"is_corresponding":false},{"id":1687386,"name":"Philipp Gödel","orcid":null,"position":8,"is_corresponding":false},{"id":1687387,"name":"Marcel Schmiel","orcid":null,"position":9,"is_corresponding":false},{"id":1687388,"name":"Jörn Meinel","orcid":null,"position":10,"is_corresponding":false},{"id":470963,"name":"Ruth Flümann","orcid":"0000-0002-7147-7557","position":11,"is_corresponding":false},{"id":1602594,"name":"Florian Simon","orcid":"0000-0002-2700-3717","position":12,"is_corresponding":false},{"id":1588945,"name":"H. Christian Reinhardt","orcid":null,"position":13,"is_corresponding":false},{"id":1130852,"name":"Peter Borchmann","orcid":"0000-0003-3782-2158","position":14,"is_corresponding":false},{"id":1586004,"name":"Sven Borchmann","orcid":null,"position":15,"is_corresponding":false},{"id":84446,"name":"Hyatt Balke‐Want","orcid":"0000-0002-5963-7626","position":16,"is_corresponding":false},{"id":470983,"name":"Gero Knittel","orcid":"0000-0001-8395-3701","position":17,"is_corresponding":false},{"id":95436,"name":"Bastian von Tresckow","orcid":"0000-0003-1410-4487","position":18,"is_corresponding":false},{"id":1687381,"name":"Jan‐Michel Heger","orcid":"0000-0001-9463-8504","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet <scp>PCR</scp>","abstract":"<jats:title>Abstract</jats:title><jats:p>Although several promising approaches for the treatment of relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long‐term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously untreated DLBCL, but data on the repeated assessment of MRD in the dynamic course of rrDLBCL is limited. Here, we present an approach leveraging cost‐ and time‐sensitivity of digital droplet (dd)PCR to repeatedly assess MRD in rrDLBCL and present proof‐of‐principle for its ability to predict outcomes.</jats:p>","is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38369814","pmcid":null,"openalex_id":"https://openalex.org/W4391943693","authors":[],"funders":[{"funder_name":"Deutsche Krebshilfe","grant_id":"70113307","title":null},{"funder_name":"Deutsche Krebshilfe","grant_id":"1117240","title":null},{"funder_name":"Deutsche Krebshilfe","grant_id":"70113041","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"RE 2246/13‐1","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"SFB1399‐A01","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"SFB1430‐A09","title":null},{"funder_name":"Else Kröner-Fresenius Stiftung","grant_id":"EKFS-2014-A06","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"RE 2246/13-1","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"SFB1430-A09","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"SFB1399-A01","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"unidentified","title":"unidentified"},{"funder_name":"Novartis","grant_id":"","title":null},{"funder_name":"Else Kröner-Fresenius-Stiftung","grant_id":"","title":null},{"funder_name":"EKFS","grant_id":"","title":null},{"funder_name":"Else Kröner-Fresenius-Stiftung","grant_id":"","title":null},{"funder_name":"Novartis","grant_id":"","title":null}],"total_grants":16,"fwci":2.4198,"citation_percentile":0.8828886,"influential_citations":0,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":3},{"year":2026,"count":3}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.14191","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.14191","host_type":"HYBRID"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.14191","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.14191","host_type":"publisher"},{"url":"https://doi.org/10.1111/ejh.14191","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38369814","host_type":"repository"},{"url":"https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85186209614","host_type":""},{"url":"https://www.ncbi.nlm.nih.gov/pubmed/38369814","host_type":""}],"fields_of_study":["Lymphoma Diagnosis and Treatment","CAR-T cell therapy research","Immune Cell Function and Interaction","Medicine","0301 basic medicine","0303 health sciences","03 medical and health sciences","Humans","Neoplasm, Residual","Lymphoma, Large B-Cell, Diffuse","Polymerase Chain Reaction","Antineoplastic Combined Chemotherapy Protocols","Recurrence","Prognosis","Circulating Tumor DNA","Male","Female","Drug Resistance, Neoplasm","Biomarkers, Tumor","Middle Aged","Treatment Outcome"],"mesh_terms":["Circulating Tumor DNA","Antineoplastic Combined Chemotherapy Protocols","Female","Humans","Male","Middle Aged","Prognosis","Recurrence","Biomarkers, Tumor","Polymerase Chain Reaction","Lymphoma, Large B-Cell, Diffuse","Treatment Outcome","Neoplasm, Residual","Drug Resistance, Neoplasm"],"keywords":["Minimal residual disease","Digital polymerase chain reaction","Refractory (planetary science)","Circulating tumor DNA","Medicine","Residual","Lymphoma","Oncology","Internal medicine","Disease","Diffuse large B-cell lymphoma","Polymerase chain reaction","Computational biology","Computer science","Cancer","Biology","Algorithm","Leukemia","Gene","ctDNA","Mrd","Ddpcr","Liquid Biopsy","Lbcl","Male","Neoplasm, Residual","Medizin","Middle Aged","Prognosis","Treatment Outcome","Recurrence","Drug Resistance, Neoplasm","Antineoplastic Combined Chemotherapy Protocols","Biomarkers, Tumor","Humans","Female","Lymphoma, Large B-Cell, Diffuse"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T01:37:54.088510Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}